Shanghai Pharmaceuticals buys out Cardinal Health in China to become top distributor of imported drugs

Liu expects Shanghai Pharmaceuticals Holding’s investment in Cardinal to reap a return in eight to nine years. With a rapidly ageing population, the Chinese government has issued several new industry policies in an attempt to reform and improve the …
( read original story …)

Related Post